- $257.51m
- $151.24m
- $53.74m
Q32 Bio soars after $55 mln equity raise at a premium
Brief: Q32 Bio Announces $55 Million Private Placement Financing
Brief: Q32 Bio Inc Files Additional Prospectus To Offer Up To $75 Million Of Common Stock
Brief: Q32 Bio Enters Agreement For Issuance & Sale Of About 1.7 Mln Shares At $3.90 Per Share
Brief: Q32 Bio Announces $10.5 Million Registered Direct Offering
Brief: Akebia Announces Establishment Of Rare Kidney Disease Pipeline
Brief: Q32 Bio Sells Complement Inhibitor Adx-097
Q32 Bio Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Q32 Bio Reports Second Quarter 2025 Financial Results And Provides Corporate Update
Q32 Bio Inc expected to post a loss of 98 cents a share - Earnings Preview
Brief: Q32 Bio Appoints Adrien Sipos As Interim Chief Medical Officer
Q32 Bio Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Q32 Bio Reports First Quarter 2025 Financial Results And Provides Corporate Update
Q32 Bio Inc expected to post a loss of $1.23 a share - Earnings Preview
Brief: Q32 Bio Announces FDA Fast Track Designation Granted To Bempikibart (ADX-914) For The Treatment Of Alopecia Areata
Brief: Q32 Bio Inc - Mark Iwicki Resigns From Q32 Bio Board Effective Dec 31, 2025
Brief: Q32 Bio Doses First Patients In Both Part A Open-Label Extension And Part B Of Signal-Aa Phase 2A Trial
Brief: Q32 Bio Files For Mixed Shelf Of Up To $200 Million - SEC Filing
Q32 Bio Inc reports results for the quarter ended December 31 - Earnings Summary